In particular, patients with aberrant expression of CDKN2A/P16, TP53 and SMAD4/DPC4 exhibited higher levels of several metabolic enzymes, including ALDOA, compared to patients with only one of these mutations, suggesting a relationship between genetic mutations and aberrant metabolism in PDA [157]. The gene discussed is ALDOA; the disease is Patent ductus arteriosus.